|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Written by Jeffrey Neal Johnson. Article Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Whitney Tilson - the Wall Street analyst who called the 2000 dot-com collapse and appeared on an Emmy-winning 60 Minutes segment covering the 2008 financial crisis - is issuing what he calls his most urgent warning yet.
Tilson says the next six months will bring extreme change for millions of Americans, and he's outlined specific steps to protect your money - moves he believes could outperform stocks, bonds, and gold. Access Tilson's full preparation plan here, free of charge
Abbott Laboratories’ stock price recently hit a 52-week low, closing just above $100 in the final trading days of March. This sharp downturn has many asking whether the foundation of this industry leader is cracking. A closer look at Abbott’s current situation suggests a possible disconnect between market sentiment and operational reality. The key question for investors is whether the market’s pessimism is warranted or if a meaningful value opportunity has emerged for long-term buyers. Separating the Signal From the NoiseA stock like Abbott doesn’t fall without reason. Two distinct pressures explain the recent decline. The first is an internal headwind: the Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily driven by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been candid about the challenge and outlined a plan to turn things around. CEO Robert B. Ford described pricing and promotion initiatives and a pipeline of at least eight new product launches planned for 2026, with management forecasting a return to volume growth in the second half of the year. The second factor is external and broader in scope. The market has been rotating capital toward higher-beta areas. In periods of economic optimism, investors often shift funds away from defensive sectors like the healthcare sector and into sectors such as artificial intelligence (AI) and energy in pursuit of faster returns. That broad trend has pressured many fundamentally sound healthcare stocks, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core remains solid, powered by its largest and most profitable division: Medical Devices. That segment is not just stable — it is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s strongest areas make the firm’s overall health clear.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a major growth driver. This product line, which lets users track glucose levels without routine fingersticks, generated more than $7.5 billion in sales in 2025 and continues to underpin Abbott’s sustained momentum. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This strength comes from a portfolio of best-in-class products such as MitraClip and TriClip, and from a pipeline that includes recent FDA clearance of the Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through a major strategic move: the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. This deal would immediately expand Abbott’s presence in the rapidly growing, multi-billion-dollar market for cancer diagnostics, adding a new, high-growth vertical that could contribute meaningfully to revenue over time. Professional analysts appear to agree with this constructive view. Wall Street maintains a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47 — implying potential upside of roughly 30% from current levels and signaling that many expect the stock to rebound. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, the exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a deep commitment to returning capital to shareholders through different market cycles. The recent drop in Abbott’s stock price has a direct benefit for new income investors: a higher dividend yield. At current levels, Abbott offers a yield of about 2.5%, allowing investors to lock in a stronger income rate from a historically reliable payer. The dividend also appears secure: the payout ratio is roughly 68% of earnings, and the dividend represents about 37% of cash flow — indicating Abbott generates ample cash to cover payments and retain room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the company’s business fundamentals. Temporary headwinds in a single division and broader market rotation have weighed on the stock, while Abbott’s core growth engines are accelerating. Its Medical Devices division continues to perform strongly, its dividend remains a reliable income source, and strategic catalysts like the Exact Sciences acquisition could add significant growth. For investors with a long-term horizon, the present valuation suggests a meaningful gap between price and intrinsic value and may represent a compelling buying opportunity. |
